Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine
AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the AntiClastic ASO platform, to chair Alloy’s genetic medicines scientific advisory board (SAB). BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Alloy Therapeutics enables high-throughput CAR discovery and engineering by providing diverse binder sets from its ATX-Gx™ and ATX-SiD platforms to optimize antigen specificity and affinity. Their Discovery Services offer comprehensive functional screening in primary immune cells—including expression, activation, and cell-killing assays—to streamline the development of next-generation CAR-T, NK, and macrophage therapies. Cell therapy utilizing chimeric […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Alloy Therapeutics is democratizing access to foundational drug delivery, formulation, and half-life extension technologies to overcome critical barriers such as molecular stability and crossing the blood-brain barrier. Through its Innovation Subscription model and collaborations with institutions like MIT’s Marble Center, Alloy provides the drug discovery community with validated, pre-competitive delivery platforms including LNPs and antibody-drug […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Alloy Therapeutics is expanding into genetic medicines with its ASO Discovery Services group, offering democratized access to novel chemistries, bioinformatics-driven design, and ASO-antibody conjugates. Led by industry pioneers Dr. Sudhir Agrawal and Dr. Ben Chih, this initiative aims to overcome historical toxicity and accessibility barriers to unlock the full therapeutic potential of antisense oligonucleotides. Our […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Partnering with Target-Rich Biotech Companies
Alloy Therapeutics collaborates with “target-rich” biotech companies through its 82VS venture studio to launch asset-centric joint ventures that accelerate drug discovery. By providing end-to-end Discovery Services and company creation support, Alloy enables partners to produce high-value targets and move promising treatments toward the clinic without traditional capital constraints. Running a successful early-stage biotech company requires […]